Loading...
Market
How will 23andMe's restructuring affect employee satisfaction by end of 2025?
1
Resolution / Starting Odds
Significantly improved • 25%
Slightly improved • 25%
Unchanged • 25%
Declined • 25%
Employee satisfaction surveys or Glassdoor reviews
Story
23andMe to Lay Off 200 Employees, Discontinue Therapeutics to Focus on Core Genetics Business
Nov 12, 2024, 12:41 AM
Genetic testing company 23andMe announced plans to lay off 40% of its workforce, or roughly 200 employees, incurring up to $12 million in one-time costs as part of a restructuring effort to streamline operations and reduce costs. The firm will discontinue its therapeutics division, effectively exiting the drug development business, to focus on its core consumer genetics offerings. The decision marks a significant shift for the company, which had previously embarked on drug discovery initiatives leveraging its vast genetic data.
View original story
Similar markets
Less than 300 • 25%
300 to 500 • 25%
501 to 700 • 25%
More than 700 • 25%
Successful privatization • 25%
Abandoned privatization plan • 25%
Privatization plan still in progress • 25%
Other outcome • 25%
Successfully privatized • 25%
Plan abandoned • 25%
Plan delayed • 25%
Other • 25%
Above 50% increase • 25%
10% to 50% increase • 25%
0% to 10% increase • 25%
Decrease • 25%
Anne Wojcicki remains CEO • 25%
New CEO appointed from internal candidate • 25%
New CEO appointed from external candidate • 25%
Interim CEO appointed • 25%
Successful privatization • 25%
Abandoned privatization • 25%
New buyout offer • 25%
Other outcome • 25%
Outperforms NASDAQ • 25%
Performs on par with NASDAQ • 25%
Underperforms NASDAQ • 25%
Delisted from NASDAQ • 25%